Courier received more than 500 million U.S. dollars in its first appearance. This cutting-edge company wants to revolutionize the development of new drugs for brain diseases

▎The content team editor of WuXi AppTec today, Neumora Therapeutics announced that it will move out of the hidden mode and will integrate data science and neuroscience to develop precision therapies for brain diseases including depression and Alzheimer's disease
.

On the same day, the company also announced a R&D cooperation with Amgen, obtaining US$100 million in equity investment from Amgen and developing R&D projects targeting casein kinase 1 delta (casein kinase 1 delta) and glucocerebrosidase.

.

This cooperation also allows the company's total financing to exceed 500 million US dollars
.

In the past few decades, drug development in the field of neuroscience has been facing multiple challenges, and many brain diseases lack effective targeted therapies
.

The reason is that brain diseases are usually driven by a variety of complex factors, and patients have a very high heterogeneity
.

Therefore, if only clinical symptoms are used to classify patients, it may reduce the success rate of new drug development due to significant differences between patients
.

Neumora's goal is to apply the research and development strategy of anti-cancer drugs and rare disease drugs to the development of brain disease drugs
.

Use a precision digital science platform to subdivide patients with neuropsychological diseases and neurodegenerative diseases, find specific patient subgroups, and pair them with targeted targeted therapies to get the best treatment effect
.

Image source: Neumora's official website.
The company's collaboration with Amgen will use the human genome, health and disease data from Amgen's deCODE genentic subsidiary to enhance drug discovery and development
.

Neumora's unique neural network technology will integrate genomics, imaging, EEG, and clinical data to discover the inner mechanism of brain diseases and outline specific patient subtypes
.

At present, there are already 8 research projects in Neumora's R&D pipeline
.

Among them, MNRA-140, which is used to treat depression, has entered phase 2 clinical trials
.

The development of this drug also reflects the company's precision medicine strategy
.

MNRA-140 is unique in that it can treat the symptoms of depression patients who cannot feel happy
.

The company will use a screening technology to generate a digital biomarker based on the patient's answers in the questionnaire and find the most suitable patient for this therapy
.

"There are very few effective targeted therapies for the treatment of brain diseases
.

" Mr.
Paul L.
Berns, CEO of Neumora, said: "We now have the tools and technologies to redefine brain diseases
.

They will revolutionize the development of targeted precision therapies
.

We were established.
Neumora's goal is to develop potential'best-in-class' precision treatments for brain diseases, and we believe that integrating data science will be the key
.

"Reference: [1] Neumora Therapeutics Launches to Pioneer a New Era of Precision Medicines for Brain Diseases.
Retrieved October 7, 2021, from https:// Amgen and Neumora Therapeutics Announce Strategic R&D Collaboration to Accelerate Novel Precision Therapies for Brain Diseases.
Retrieved October 7, 2021, from https://neumoratx.
com/news/amgen-and-neumora-therapeutics-announce-strategic-rd-collaboration-to -accelerate-novel-precision-therapies-for-brain-diseases/[3] Neumora Therapeutics.
Retrieved October 7, 2021, from https://neumoratx.
com/ Disclaimer: WuXi AppTec's content team focuses on introducing global biomedical health Research progress
.

This article is for the purpose of information exchange only.
The opinions in the article do not represent WuXi AppTec’s position, nor does it mean that WuXi AppTec supports or opposes the views
in the
article .
This article is not a treatment plan recommendation
.

If you need treatment plan guidance, please go to a regular hospital See a doctor
.